Russell Investments Group Ltd. Acquires 4,426 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Russell Investments Group Ltd. increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) by 13.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,772 shares of the biopharmaceutical company’s stock after acquiring an additional 4,426 shares during the quarter. Russell Investments Group Ltd. owned about 0.07% of Agios Pharmaceuticals worth $1,061,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $54,411,000. Fisher Asset Management LLC acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $23,738,000. UBS Asset Management Americas Inc. lifted its position in shares of Agios Pharmaceuticals by 635.7% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 476,013 shares of the biopharmaceutical company’s stock worth $10,553,000 after acquiring an additional 411,312 shares during the period. First Trust Advisors LP grew its holdings in shares of Agios Pharmaceuticals by 27.2% during the 1st quarter. First Trust Advisors LP now owns 1,613,429 shares of the biopharmaceutical company’s stock worth $46,967,000 after purchasing an additional 344,959 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Agios Pharmaceuticals by 39.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,010,616 shares of the biopharmaceutical company’s stock valued at $29,420,000 after purchasing an additional 285,215 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on AGIO shares. Piper Sandler began coverage on shares of Agios Pharmaceuticals in a research note on Friday, February 3rd. They set an “overweight” rating and a $41.00 price target on the stock. SVB Securities decreased their target price on shares of Agios Pharmaceuticals from $37.00 to $34.00 in a research report on Friday, May 5th. Piper Jaffray Companies started coverage on shares of Agios Pharmaceuticals in a research report on Friday, February 3rd. They issued an “overweight” rating and a $41.00 price target for the company. Finally, StockNews.com began coverage on Agios Pharmaceuticals in a report on Thursday, May 18th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $37.00.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director David P. Schenkein sold 20,000 shares of the stock in a transaction on Monday, March 27th. The stock was sold at an average price of $22.15, for a total transaction of $443,000.00. Following the sale, the director now owns 117,879 shares in the company, valued at $2,611,019.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director David P. Schenkein sold 16,363 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $22.85, for a total value of $373,894.55. Following the completion of the transaction, the director now owns 117,879 shares in the company, valued at approximately $2,693,535.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David P. Schenkein sold 20,000 shares of the stock in a transaction on Monday, March 27th. The shares were sold at an average price of $22.15, for a total value of $443,000.00. Following the completion of the transaction, the director now owns 117,879 shares in the company, valued at $2,611,019.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,867 shares of company stock worth $1,278,937. 4.24% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Down 3.4 %

Shares of Agios Pharmaceuticals stock opened at $25.78 on Friday. Agios Pharmaceuticals, Inc. has a 12-month low of $16.75 and a 12-month high of $34.76. The stock has a market capitalization of $1.43 billion, a P/E ratio of -6.49 and a beta of 0.96. The company has a 50-day simple moving average of $23.49 and a 200 day simple moving average of $26.40.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($1.59) by $2.26. The company had revenue of $4.31 million during the quarter, compared to analyst estimates of $4.42 million. Agios Pharmaceuticals had a negative net margin of 1,146.58% and a negative return on equity of 20.23%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.16 earnings per share for the current year.

Agios Pharmaceuticals Profile

(Get Rating)

Agios Pharmaceuticals, Inc is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.